Compare PSNY & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNY | HROW |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | PSNY | HROW |
|---|---|---|
| Price | $17.04 | $33.90 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $15.00 | ★ $71.14 |
| AVG Volume (30 Days) | 175.6K | ★ 992.4K |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.59 | $32.90 |
| Revenue Next Year | $31.71 | $48.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $20.85 |
| 52 Week High | $23.28 | $54.98 |
| Indicator | PSNY | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 34.70 |
| Support Level | $15.55 | $32.55 |
| Resistance Level | $19.00 | $41.49 |
| Average True Range (ATR) | 0.95 | 1.54 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 48.75 | 19.45 |
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.